Infinity (INFI) Appoints Two New Independent Board Memebers
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Join SI Premium – FREE
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has appointed Gwen A. Fyfe, M.D., and Norman C. Selby as independent members of its board of directors. Dr. Fyfe is an oncology biotechnology veteran with more than 20 years of drug development experience, most recently at Genentech, Inc. Mr. Selby is a seasoned business leader with more than 30 years of experience leading and advising companies in the healthcare industry.
Infinity also announced today that James Tananbaum, M.D., and Arnold Levine, Ph.D., will be retiring from our board in May. Dr. Tananbaum and Dr. Levine, who have been members of Infinity’s board of directors since the founding of its predecessor company in 2001, were important contributors to Infinity’s early venture funding and initial discovery research efforts.
Infinity also announced today that James Tananbaum, M.D., and Arnold Levine, Ph.D., will be retiring from our board in May. Dr. Tananbaum and Dr. Levine, who have been members of Infinity’s board of directors since the founding of its predecessor company in 2001, were important contributors to Infinity’s early venture funding and initial discovery research efforts.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Genworth Financial CEO returns from leave of absence in September
- Sky Quarry names Heidi Bowman as CFO
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
